Department of Pneumology and Critical Care Medicine, Thoraxklinik-Heidelberg GmbH, Translational Lung Research Center Heidelberg (TLRC), Heidelberg, Germany
Biomedical Research in Endstage and Obstructive Lung Disease (BREATH), Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, Hannover, Germany.
BMJ Open Respir Res. 2020 Dec;7(1). doi: 10.1136/bmjresp-2020-000741.
This exploratory, randomised, double-blind, double-dummy, multicentre, cross-over study explored the effect of 6 weeks of treatment with tiotropium/olodaterol (T/O) versus fluticasone propionate/salmeterol (F/S) on left ventricular filling in patients with chronic obstructive pulmonary disease with functional residual capacity (FRC) >120% predicted and postbronchodilator improvement of FRC ≥7.5%. Overall, 76 patients were randomised across nine sites. Treatment with T/O or F/S increased left ventricular end-diastolic volume index from baseline (adjusted mean change: T/O: 2.317 mL/m, F/S: 2.855 mL/m), with no statistically significant difference between treatments. However, T/O resulted in a significantly greater reduction in lung hyperinflation versus F/S (FRC plethysmography absolute change from baseline: F/S: -0.329 L, T/O: -0.581 L).
这项探索性、随机、双盲、双模拟、多中心、交叉研究探讨了 6 周噻托溴铵/奥达特罗（T/O）治疗与丙酸氟替卡松/沙美特罗（F/S）治疗对功能残气量（FRC）>120%预测值且支气管扩张剂后 FRC 改善≥7.5%的慢性阻塞性肺疾病患者左心室充盈的影响。共有 76 名患者在 9 个地点被随机分组。与基线相比，T/O 或 F/S 治疗均可增加左心室舒张末期容积指数（调整后的平均变化：T/O：2.317 mL/m，F/S：2.855 mL/m），治疗之间无统计学差异。然而，与 F/S 相比，T/O 可显著降低肺过度充气（FRC 体描法绝对值从基线变化：F/S：-0.329 L，T/O：-0.581 L）。
